Reduced activity of adenylyl cyclase 1 attenuates morphine induced hyperalgesia and inflammatory pain in mice
Related Experiment Video
Updated: Aug 28, 2025

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
Kayla Johnson1, Alexis Doucette1, Alexis Edwards1
1Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, MN, United States.
Abstract:
Opioid tolerance, opioid-induced hyperalgesia during repeated opioid administration, and chronic pain are associated with upregulation of adenylyl cyclase activity. The objective of this study was to test the hypothesis that a reduction in adenylyl cyclase 1 (AC1) activity or expression would attenuate morphine tolerance and hypersensitivity, and inflammatory pain using murine models. To investigate opioid tolerance and opioid-induced hyperalgesia, mice were subjected to twice daily treatments of saline or morphine using either a static (15 mg/kg, 5 days) or an escalating tolerance paradigm (10-40 mg/kg, 4 days). Systemic treatment with an AC1 inhibitor, ST03437 (2.5-10 mg/kg, IP), reduced morphine-induced hyperalgesia in mice. Lumbar intrathecal administration of a viral vector incorporating a short-hairpin RNA targeting Adcy1 reduced morphine-induced hypersensitivity compared to control mice. In contrast, acute morphine antinociception, along with thermal paw withdrawal latencies, motor performance, exploration in an open field test, and burrowing behaviors were not affected by intrathecal Adcy1 knockdown. Knockdown of Adcy1 by intrathecal injection also decreased inflammatory mechanical hyperalgesia and increased burrowing and nesting activity after intraplantar administration of Complete Freund's Adjuvant (CFA) one-week post-injection.
Insights
Reducing adenylyl cyclase 1 (AC1) activity or expression attenuates morphine tolerance and hypersensitivity. This approach also decreased inflammatory pain and improved nesting behaviors in mice.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Opioid tolerance, opioid-induced hyperalgesia, and chronic pain are linked to increased adenylyl cyclase activity.
- Adenylyl cyclase 1 (AC1) is implicated in these opioid-related pain states.
Purpose of the Study:
- To investigate if reducing AC1 activity or expression can alleviate morphine tolerance, hyperalgesia, and inflammatory pain.
- To test the therapeutic potential of targeting AC1 in pain management.
Main Methods:
- Murine models were used to study opioid tolerance and hyperalgesia with static or escalating morphine treatment paradigms.
- Systemic administration of an AC1 inhibitor (ST03437) and intrathecal delivery of a viral vector with short-hairpin RNA targeting Adcy1 were employed.
- Inflammatory pain was induced using Complete Freund's Adjuvant (CFA), and behavioral tests assessed antinociception, motor performance, and nesting activities.
Main Results:
- Systemic AC1 inhibition reduced morphine-induced hyperalgesia.
- Intrathecal Adcy1 knockdown attenuated morphine-induced hypersensitivity without affecting acute antinociception or motor functions.
- Adcy1 knockdown decreased inflammatory mechanical hyperalgesia and enhanced nesting behaviors post-CFA administration.
Conclusions:
- Reducing AC1 activity or expression is a viable strategy to mitigate opioid-induced hyperalgesia and tolerance.
- Targeting AC1 shows promise for managing inflammatory pain and improving well-being in pain models.
Related Concept Videos
Analgesia and Pain Management
Opioid Receptors: Overview
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
GPCRs Regulate Adenylyl Cylase Activity
Nociception

